目的 观察胰腺癌患者血浆中组织因子途径抑制物_2( TFPI-2)基因启动子区甲基化状态,并探讨其临床意义.方法 采用甲基化特异性聚合酶链反应(MSP)检测62例胰腺癌患者(观察组)及30例胆胰非肿瘤疾病患者(对照组)血浆中的TFPI-2基因甲基化状态.结果 观察组血浆TFPI-2基因甲基化阳性率为66.13% (41/62),明显高于正常对照组的3.33% (1/30),P＜0.01.血浆TFPI-2基因甲基化与胰腺癌的临床分期、组织分化程度有关(P均＜0.05).结论 胰腺癌患者血浆中TFPI-2基因出现异常甲基化；血浆TFPI-2基因甲基化检测可能有助于胰腺癌的早期诊断.%Objective To investigate the tissue factor pathway inhibitor (TFPI)-2 gene promoter aberrant methylation in the plasma of patients with pancreatic cancer and analyse its possible clinical signifiance. Methods Methylation-specif-ic PCR was used to detect promoter methylation of the TFPI-2 gene in the plasma from 62 patients with pancreatic cancer and 30 nontumorous patients. Results Promoter methylation of TFPI-2 was found in 66.13% (41/62) of pancreatic cancer patients and 3. 33 % (1/30) of control samples (P < 0.01). The positive rate of TFPI-2 methylation was related to clinical stage,tissue differentiation of carcinoma(P <0.05). Conclusion There is aberrant methylation of TFPI-2 gene in pancreatic cancer patients plasma, which may be helpful for early diagnosis of pancreatic cancer.
展开▼
